5 research outputs found

    Π­Ρ„Ρ„Π΅ΠΊΡ‚ΠΈΠ²Π½ΠΎΡΡ‚ΡŒ использования Π±Π°ΠΊΡ‚Π΅Ρ€ΠΈΠΎΡ„Π°Π³ΠΎΠ² для лСчСния ΠΈ ΠΏΡ€ΠΎΡ„ΠΈΠ»Π°ΠΊΡ‚ΠΈΠΊΠΈ ΠΈΠ½Ρ„Π΅ΠΊΡ†ΠΈΠΈ: систСматичСский ΠΎΠ±Π·ΠΎΡ€

    Get PDF
    Successful implementation of lytic virulent bacteriophages in clinical practice requires convincing evidence of its safety and efficacy.Design: We searched in CENTRAL, MEDLINE, Embase, and Russian-language literature databases in May 2018. Original articles must fulfill the following eligibility criteria: randomized, controlled trials investigating the effects of phage therapy in people with bacterial infections; at least one patient outcome was reported. Three review authors independently selected, studies, extracted, data, and. assessed, risk of bias. We used, random-effects models for meta-analysis.Participants: adults and. children of both, sexes with bacterial infection, including multi-drug resistant variants, or individuals at risk of infection.Outcomes: recovery or resolution of infection; clinical improvement; change in number of exacerbations; recurrence of infection; quality of life; elimination or load, reduction of a pathogen in an anatomical compartment.Results: We included 13 trials (issued in 1965-2018) including 9 treatment studies and. 4 prevention studies. Overall, eight randomized, trials involved, adults. Five studies addressed skin and soft tissues infections, six studies concerned intestinal infections, one study addressed respiratory tract infection and. one study β€” ear infection. Across bias domains, 35-90% of trials scored, low risk of bias. Meta-analysis for adverse events attributable to phages and. for wound, healing provided us with pooled relative risks of 0.74 (95% CI 0.68;1.2) and 0.91 (95% CI0.68;1.2) respectively.Conclusions: Beneficial effect of bacteriophages can be demonstrated, and. not refuted. However, our study led. to tentative conclusions. The conduct of well-designed and sufficiently powered, trials would, facilitate registration and. wide accepting of bacteriophage treatment.ЦСль: ΠΎΡ†Π΅Π½ΠΊΠ° использования Π±Π°ΠΊΡ‚Π΅Ρ€ΠΈΠΎΡ„Π°Π³ΠΎΠ², примСняСмых для ΠΏΡ€ΠΎΡ„ΠΈΠ»Π°ΠΊΡ‚ΠΈΠΊΠΈ ΠΈΠ»ΠΈ лСчСния Π±Π°ΠΊΡ‚Π΅Ρ€ΠΈΠ°Π»ΡŒΠ½Ρ‹Ρ… ΠΈΠ½Ρ„Π΅ΠΊΡ†ΠΈΠΉ Ρƒ людСй.ΠœΠ΅Ρ‚ΠΎΠ΄: поиск ΠΈΠ½Ρ„ΠΎΡ€ΠΌΠ°Ρ†ΠΈΠΈ ΠΏΡ€ΠΎΠ²Π΅Π΄Π΅Π½ Π² Π°Π½Π³Π»ΠΎ- ΠΈ русскоязычных Π±Π°Π·Π°Ρ… Π΄Π°Π½Π½Ρ‹Ρ… Π² 2018 Π³. ΠšΡ€ΠΈΡ‚Π΅Ρ€ΠΈΠΈ ΠΎΡ‚Π±ΠΎΡ€Π° ΠΎΡ€ΠΈΠ³ΠΈΠ½Π°Π»ΡŒΠ½Ρ‹Ρ… статСй: Ρ€Π°Π½Π΄ΠΎΠΌΠΈΠ·ΠΈΡ€ΠΎΠ²Π°Π½Π½Ρ‹Π΅ ΠΊΠΎΠ½Ρ‚Ρ€ΠΎΠ»ΠΈΡ€ΡƒΠ΅ΠΌΡ‹Π΅ испытания; описан ΠΊΠ°ΠΊ ΠΌΠΈΠ½ΠΈΠΌΡƒΠΌ, ΠΎΠ΄ΠΈΠ½ исход, Π·Π½Π°Ρ‡ΠΈΠΌΡ‹ΠΉ для ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚Π°; взрослыС ΠΈ Π΄Π΅Ρ‚ΠΈ, ΠΎΠ±ΠΎΠ΅Π³ΠΎ ΠΏΠΎΠ»Π°, с Π΄ΠΈΠ°Π³Π½ΠΎΠ·ΠΎΠΌ Π±Π°ΠΊΡ‚Π΅Ρ€ΠΈΠ°Π»ΡŒΠ½ΠΎΠΉ ΠΈΠ½Ρ„Π΅ΠΊΡ†ΠΈΠΈ ΠΈΠ»ΠΈ Π»ΠΈΡ†Π° с риском, зараТСния. Π’Ρ€ΠΈ Π°Π²Ρ‚ΠΎΡ€Π° нСзависимо Π΄Ρ€ΡƒΠ³ ΠΎΡ‚ Π΄Ρ€ΡƒΠ³Π° ΠΎΡ‚Π±ΠΈΡ€Π°Π»ΠΈ исслСдования, ΠΈΠ·Π²Π»Π΅ΠΊΠ°Π»ΠΈ Π΄Π°Π½Π½Ρ‹Π΅ ΠΈ ΠΎΡ†Π΅Π½ΠΈΠ²Π°Π»ΠΈ риск систСматичСской ошибки. Для ΠΌΠ΅Ρ‚Π°-Π°Π½Π°Π»ΠΈΠ·Π° использована модСль случайных эффСктов. Π˜ΡΡ…ΠΎΠ΄Ρ‹: Π²Ρ‹Π·Π΄ΠΎΡ€ΠΎΠ²Π»Π΅Π½ΠΈΠ΅; клиничСскоС ΡƒΠ»ΡƒΡ‡ΡˆΠ΅Π½ΠΈΠ΅; ΠΈΠ·ΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ числа обострСний; Ρ€Π΅Ρ†ΠΈΠ΄ΠΈΠ² ΠΈΠ½Ρ„Π΅ΠΊΡ†ΠΈΠΈ; качСство ΠΆΠΈΠ·Π½ΠΈ; элиминации ΠΈΠ»ΠΈ ΡƒΠΌΠ΅Π½ΡŒΡˆΠ΅Π½ΠΈΠ΅ Π½Π°Π³Ρ€ΡƒΠ·ΠΊΠΈ ΠΏΠ°Ρ‚ΠΎΠ³Π΅Π½Π° Π² анатомичСском, локусС.Π Π΅Π·ΡƒΠ»ΡŒΡ‚Π°Ρ‚Ρ‹: послС критичСской ΠΎΡ†Π΅Π½ΠΊΠΈ Π»ΠΈΡ‚Π΅Ρ€Π°Ρ‚ΡƒΡ€Ρ‹, ΠΌΡ‹. Π²ΠΊΠ»ΡŽΡ‡ΠΈΠ»ΠΈ 13 ΠΏΡƒΠ±Π»ΠΈΠΊΠ°Ρ†ΠΈΠΉ: исслСдования лСчСния (n = 9) ΠΈ исслСдования ΠΏΡ€ΠΎΡ„ΠΈΠ»Π°ΠΊΡ‚ΠΈΠΊΠΈ (ΠΏ = 4). Из Π½ΠΈΡ… 5 исслСдований Π±Ρ‹Π»ΠΈ ΠΏΡ€ΠΎΠ²Π΅Π΄Π΅Π½Ρ‹, Π² России ΠΈ Π±Ρ‹Π²ΡˆΠ΅ΠΌ. Π‘Π‘Π‘Π , 3 β€” Π² БША, 2 β€” Π² Π—Π°ΠΏΠ°Π΄Π½ΠΎΠΉ Π•Π²Ρ€ΠΎΠΏΠ΅, 2β€”Π² Азии. 8 исслСдований Π±Ρ‹Π»ΠΎ с участиСм взрослых ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΎΠ². 5 Ρ€Π°Π±ΠΎΡ‚ касались ΠΈΠ½Ρ„Π΅ΠΊΡ†ΠΈΠΉ ΠΊΠΎΠΆΠΈ ΠΈ мягких Ρ‚ΠΊΠ°Π½Π΅ΠΉ, 6 β€” ΠΊΠΈΡˆΠ΅Ρ‡Π½Ρ‹Ρ… ΠΈΠ½Ρ„Π΅ΠΊΡ†ΠΈΠΉ, 1 β€” ΠΈΠ½Ρ„Π΅ΠΊΡ†ΠΈΠΈ Π΄Ρ‹Ρ…Π°Ρ‚Π΅Π»ΡŒΠ½Ρ‹Ρ… ΠΏΡƒΡ‚Π΅ΠΉ, 1 β€” Π±ΠΎΠ»Π΅Π·Π½ΠΈ ΡƒΡ…Π°. Π’ΠΊΠ»ΡŽΡ‡Π΅Π½Π½Ρ‹Π΅ исслСдования Π±Ρ‹Π»ΠΈ ΠΎΠΏΡƒΠ±Π»ΠΈΠΊΠΎΠ²Π°Π½Ρ‹, Π² 1965β€”2018 Π³Π³. По всСм, Π²ΠΈΠ΄Π°ΠΌ, систСматичСской ошибки 35β€”90% РКИ ΠΈΠΌΠ΅Π»ΠΈ Π½ΠΈΠ·ΠΊΠΈΠΉ риск. ΠœΠ΅Ρ‚Π°-Π°Π½Π°Π»ΠΈΠ· Π±Ρ‹Π» Π²ΠΎΠ·ΠΌΠΎΠΆΠ΅Π½ Ρ‚ΠΎΠ»ΡŒΠΊΠΎ для ΠΏΠΎΠ±ΠΎΡ‡Π½Ρ‹Ρ… явлСний, связанных с Ρ„Π°Π³Π°ΠΌΠΈ, ΠΈ для заТивлСния Ρ€Π°Π½: 0,74 (95% Π”Π˜ 0,68β€”1,2) ΠΈ 0,91 (95% Π”Π˜ 0,68β€”1,2) соотвСтствСнно.Π’Ρ‹Π²ΠΎΠ΄Ρ‹: с ΡƒΡ‡Π΅Ρ‚ΠΎΠΌ, ΡΡ„ΠΎΡ€ΠΌΠΈΡ€ΠΎΠ²Π°Π²ΡˆΠ΅ΠΉΡΡ Π΄ΠΎΠΊΠ°Π·Π°Ρ‚Π΅Π»ΡŒΠ½ΠΎΠΉ Π±Π°Π·Ρ‹, благоприятный эффСкт Ρ„Π°Π³ΠΎΡ‚Π΅Ρ€Π°ΠΏΠΈΠΈ Π½Π΅ Π²Ρ‹Π·Ρ‹Π²Π°Π΅Ρ‚ сомнСний. Однако нашС исслСдованиС позволяСт ΡΠ΄Π΅Π»Π°Ρ‚ΡŒ лишь ΠΏΡ€Π΅Π΄Π²Π°Ρ€ΠΈΡ‚Π΅Π»ΡŒΠ½Ρ‹Π΅ Π²Ρ‹Π²ΠΎΠ΄Ρ‹. Π¨ΠΈΡ€ΠΎΠΊΠΎΠ΅ ΠΏΡ€ΠΈΠ·Π½Π°Π½ΠΈΠ΅ Π±Π°ΠΊΡ‚Π΅Ρ€ΠΈΠΎΡ„Π°Π³ΠΎΠ² ΠΌΠΈΡ€ΠΎΠ²ΠΎΠΉ Π½Π°ΡƒΠΊΠΎΠΉ для лСчСния ΠΈ ΠΏΡ€ΠΎΡ„ΠΈΠ»Π°ΠΊΡ‚ΠΈΠΊΠΈ Ρ‚Ρ€Π΅Π±ΡƒΠ΅Ρ‚, провСдСния РКИ Π΄ΠΎΠ»ΠΆΠ½ΠΎΠ³ΠΎ мСтодологичСского качСства ΠΈ мощности

    EPIDEMIOLOGY OPPORTUNISTIC MYCOSES

    No full text
    The review touches upon a problem of coinfection caused by several important fungal infections (aspergillus, candida, pneumocystis, cryptococcus) and infectious or parasitic diseases. The authors also investigate epidemiologic determinants of such clinical forms of pathologic process. There are a lot of scientific gaps in the studying coinfections concerning mycosis and other infections. Physicians and infection control practitioners sometimes reveal such cases therefore complex characteristics of the coinfections is required

    GENERAL CHARACTERISTICS AND ISSUES MIXED INFECTIONS CAUSED BY OPPORTUNISTIC MICROORGANISMS

    Get PDF
    Infections caused by opportunistic microorganisms occupy a special position. In microbial associations of opportunistic microorganisms is easier to implement its low pathogenic potential, activate properties of each other. Group polyetiologic infections caused by conditionally pathogenic microorganisms are quite diverse in terms of a nosological forms and groups. These include the so-called septic infection, which are also very diverse and clinical, epidemiological and etiological characteristics. Scientific evidence shows the urgency of the problem mixed infections, especially in surgery and indicate a lack of systematic data about the whole spectrum and the composition of microbial associations in different infections, quantification, insufficient study of the properties compared to monoagents. The problem mixed infections practically not been studied with epidemiologic standpoint, only a few studies devoted to the study of nosocomial infection of microbial associations are not developed microbiological monitoring. In this connection, you need comprehensive research mixed infections compared with monoagents to identify the characteristics and development of epidemiologic surveillance and control

    Efficiency of phage therapy in humans: systematic review

    Get PDF
    Successful implementation of lytic virulent bacteriophages in clinical practice requires convincing evidence of its safety and efficacy.Design: We searched in CENTRAL, MEDLINE, Embase, and Russian-language literature databases in May 2018. Original articles must fulfill the following eligibility criteria: randomized, controlled trials investigating the effects of phage therapy in people with bacterial infections; at least one patient outcome was reported. Three review authors independently selected, studies, extracted, data, and. assessed, risk of bias. We used, random-effects models for meta-analysis.Participants: adults and. children of both, sexes with bacterial infection, including multi-drug resistant variants, or individuals at risk of infection.Outcomes: recovery or resolution of infection; clinical improvement; change in number of exacerbations; recurrence of infection; quality of life; elimination or load, reduction of a pathogen in an anatomical compartment.Results: We included 13 trials (issued in 1965-2018) including 9 treatment studies and. 4 prevention studies. Overall, eight randomized, trials involved, adults. Five studies addressed skin and soft tissues infections, six studies concerned intestinal infections, one study addressed respiratory tract infection and. one study β€” ear infection. Across bias domains, 35-90% of trials scored, low risk of bias. Meta-analysis for adverse events attributable to phages and. for wound, healing provided us with pooled relative risks of 0.74 (95% CI 0.68;1.2) and 0.91 (95% CI0.68;1.2) respectively.Conclusions: Beneficial effect of bacteriophages can be demonstrated, and. not refuted. However, our study led. to tentative conclusions. The conduct of well-designed and sufficiently powered, trials would, facilitate registration and. wide accepting of bacteriophage treatment
    corecore